Drug Database
FI

fimasartan + rosuvastatin (Tubero / Tuvero)

✓ Approved

Boryung · AGTR1 · 小分子

什么是 fimasartan + rosuvastatin?

fimasartan + rosuvastatin 是一种小分子,由Boryung研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Tubero, Tuvero
公司Boryung
药物类别小分子
分子靶点AGTR1, HMGCR
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

fimasartan + rosuvastatin 作用于 2 个分子靶点:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fimasartan + rosuvastatin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Metabolism and nutrition disordersHyperlipidaemiaPhase III

相关研究文献

PubMedAssay and drug development technologies2026-11-18

Next-Generation Oleic Acid Ufasomes: Emerging Trends in Targeted, Controlled, and Stimuli-Responsive Drug Delivery Systems.

Komal, Singh Lovekesh L

Ufasomes are vesicles formed from unsaturated fatty acids and are being investigated as carriers for pharmaceutical compounds. This review summarizes their structure, preparation methods, characterization, drug-release behavior, and emerging applications, with particular attention to reported studies involving rosuvastatin for diabetic wound healing, nintedanib for pulmonary delivery, and Glycyrrhiza glabra extract in wound dressings. Despite promising preclinical findings, translation remains limited by potential of hydrogen-dependent stability, challenges in reproducible scale-up, and insufficient safety and clinical evidence. The review critically considers these findings and identifies priorities for further development.

PMID 43046960
阅读全文 →
PubMedPloS one2026-11-16

Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study.

Dang Hai Nguyen Ngoc HNN, Nguyen Hung Minh HM, Tran Phuc Thien PT, Ho Binh Anh BA et al.

Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40-1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93-2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79-1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15-0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07-3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05-4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.

PMID 43038200
阅读全文 →
PubMedFrontiers in pharmacology2026-11-15

Atorvastatin-associated liver injury: a structured narrative review of reporting signals, clinical phenotypes, and hepatic safety, 2023-2026.

Zhang Hao H, Zhao PanLi P, Huang Hua H, Zeng YuQi Y

Atorvastatin is widely prescribed, yet its hepatic safety remains debated: randomized trials and biopsy-proven cohorts indicate acceptable safety, whereas pharmacovigilance data and case reports describe injury ranging from asymptomatic transaminase elevation to acute liver failure. PubMed was searched for records combining atorvastatin terms with liver-injury concepts, published 1 July 2023 to 31 July 2026; records were screened in duplicate and assigned to one of four outcome domains-biochemical liver test abnormality, suspected drug-induced liver injury (DILI), clinically significant or severe DILI, and acute liver failure-and were not combined across domains. This is a structured narrative review, not a systematic review: only PubMed was searched and comprehensive retrieval is not claimed. Of 119 records, 57 were included in the synthesis: 31 directly addressed atorvastatin and liver injury and 26 addressed statin hepatic safety or statin use in chronic liver disease. Among 7,779 statin-associated drug-induced liver injury (DILI) cases in FAERS (2004-2023), atorvastatin accounted for 53.48%, with a reporting odds ratio of 3.09. In 1 211 reported Chinese cases of statin-associated liver injury, the odds of severe injury were 1.77-fold higher with atorvastatin than with rosuvastatin, and 2.08-fold higher with combination therapy than with statin monotherapy. Phenotypes included hepatocellular, cholestatic and mixed injury, drug-induced autoimmune hepatitis (DIAIH) and hyperacute liver failure, usually within 2-3 months. Rechallenge reproduced injury in 12 of 16 cases, with median latency shortened from 27 to 11 days, whereas switching to a hydrophilic statin was usually tolerated. Mechanisms involve mitochondrial dysfunction, oxidative stress, CYP3A-mediated metabolic activation, bile-acid transporter inhibition and pharmacogenomic variation. Conversely, in MASLD and cirrhosis, atorvastatin did not worsen liver injury and reduced liver-related events. Severe atorvastatin-associated liver injury is rare but recognizable. Structured monitoring, causality assessment and injury phenotyping are essential, same-drug rechallenge should be avoided, and hydrophilic statins preferred. Statin therapy should not be withheld in chronic liver disease.

PMID 43032608
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Synergistic Anti-Zika Activity of Repurposed Statin and Clofibrate Combinations: Evidence from Oleic Acid-Mediated Metabolic Complementation.

Lee Chung-Do CD, Park Sang-Ik SI, Lee Gun G, Moon Hyeon Jeong HJ et al.

Zika virus (ZIKV) substantially relies on host lipid metabolism, presenting a prime target for host-directed antivirals. To identify host-directed antiviral interventions while circumventing interferon-mediated transcriptomic masking, we curated a dual-virus (dengue and ZIKV) gene signature to query the Connectivity Map. Top lipid-lowering candidates were validated using a reporter virus (rZIKV-Venus) and an authentic wild-type (WT) ZIKV in Vero E6 cells-a model deliberately selected for its interferon deficiency to isolate pure metabolic responses. Dose-response screening of 67 prioritized compounds identified atorvastatin, rosuvastatin, and clofibrate as potent ZIKV inhibitors. Statin-clofibrate combinations exhibited strong synergy, with fractional inhibitory concentration index (FICI) values of 0.203 (atorvastatin-clofibrate) and 0.117 (rosuvastatin-clofibrate) for the 4:1 clofibrate-to-statin ratio and an optimized selectivity index. Mechanistically, exogenous oleic acid supplementation induced significant metabolic complementation, significantly restoring both host lipid droplet (LD) abundance and ZIKV replication readouts suppressed by the dual treatment. Relative LD intensity strongly correlated with viral intensity in both models (Pearson r = 0.951 and 0.956, respectively; both p < 0.0001). These findings demonstrate that concurrent pharmacological modulation of host lipid metabolism exerts synergistic anti-ZIKV effects, highlighting highly curated transcriptomic repurposing as a mechanistic prioritization strategy for host-directed antiviral discovery.

PMID 43027889
阅读全文 →
PubMedCardiovascular drugs and therapy2026-11-13

Fixed-Dose Combination Versus Add-On Therapy: Clarifying the Role of Cilostazol-Rosuvastatin in Peripheral Artery Disease.

Lu Dezheng D, Kuang Chunyan C

The randomized trial by Kemalasari et al. provides evidence supporting the addition of cilostazol to rosuvastatin in patients with symptomatic peripheral artery disease. However, because the study compared the fixed-dose combination (FDC) with rosuvastatin plus placebo, it does not establish whether the FDC formulation offers advantages over an equivalent free-combination regimen. Evidence from other cardiovascular settings suggests that FDC formulations may improve medication adherence and treatment persistence, although their effects on long-term clinical outcomes remain uncertain. Future randomized studies directly comparing fixed-dose and free-combination regimens, with adherence assessed over 12 months and longer-term cardiovascular and limb outcomes evaluated, are needed to clarify the clinical value of the formulation itself.

PMID 43021022
阅读全文 →
PubMedFrontiers in aging neuroscience2026-11-13

Systems biology prioritizes drug candidates for an interferon-response-high monocyte state in idiopathic normal pressure hydrocephalus.

Haque Md Masudul MM, Bae Jongwan J, Nila Irin Sultana IS, Kang Kyunghun K et al.

Idiopathic normal pressure hydrocephalus (iNPH) is an age-associated neurological disorder characterized by gait disturbance, cognitive impairment, and urinary dysfunction. Although cerebrospinal fluid dynamics are central to its pathophysiology, the contribution of peripheral immune alterations remains poorly understood. We characterized an interferon-response-high monocyte state observed in iNPH and evaluated computational compound prioritization. We used a fixed set of marker criteria to characterize the IFN-response-high monocyte state. We then compared monocyte clusters 5 and 0 and used 150 upregulated and 150 downregulated genes to screen compounds in LINCS. We tested whether candidate rankings changed with different state definitions, comparison groups, gene-list sizes, clustering settings, and inclusion of all patients. We also repeated the queries after excluding each donor while retaining the original cell-state labels and compared the results with 100 expression-matched random gene signatures. External blood datasets and paired blood-ventricular CSF samples provided additional context. The marker rule classified 3,195 of 22,197 canonical monocytes as IFN-response-high. The cluster contrast identified 1,231 FDR-significant genes. Of 1,376 THP1 compounds, 138 met the operational criteria of normalized connectivity score (NCS) <-0.5 and WTCS FDR <0.05. Rosuvastatin and roflumilast ranked first and 14th in the primary screen and first and 15th in the integrated robustness ranking. Rosuvastatin met the operational criteria in all 11 core analyses; roflumilast did so in 10, returning NCS = 0 at resolution 0.7. Both met the criteria across all nine donor omissions. In exploratory comparisons performed after candidate selection, both observed scores were more negative than those from all 100 sampled expression-matched signatures. The blood-derived program was detectable in ventricular-CSF candidate monocytes, although unequal cell recovery limited inference about compartmental enrichment. This study characterizes an interferon-response-high classical-monocyte state observed within an iNPH cohort and nominates compounds with predicted inverse connectivity for experimental testing. Computational support was more consistent for rosuvastatin than for roflumilast. These findings support further investigation of peripheral innate immune states observed in an iNPH cohort and provide experimentally testable hypotheses for therapeutic repurposing.

PMID 43022713
阅读全文 →

注册免费账户还可查看另外 5282 篇文献

免费注册查看全部文献 →

了解更多fimasartan + rosuvastatin